Abstract

NANOCARRIER-BASED THERAPY FOR THE TREATMENT OF OSTEOARTHRITIS

Sateesh Kumar Bharati*, Ram Narayan Prajapati, Jitendra Kumar, Suman and Aman Singh

.

Abstract

Osteoarthritis (OA) is a degenerative joint disease that affects 7% of the worldwide population, more than 500 million people all over the world. OA is characterized by joint pain, low bone density, and deterioration of joint structure. OA therapy is still a big challenge as no effective treatment is available and existing treatments mainly focus on pain and symptomatic management rather than improving and suppressing its progression. The main aim of this review is to summarize the currently available various nanoformulation for the treatment of OA. The nanoparticle-loaded drug is more effective, convenient, and safer than the currently existing treatment strategy. Osteoarthritis (OA) has a unique avascular, thick, and occluded tissue structure that makes managing it a therapeutic challenge. The pathogenesis and development of OA are still not well understood despite a large number of clinical reports and animal studies. Many novel medications have been continuously developed based on conventional drugs. Targeted drug delivery systems' development is accelerated by intra-articular (IA) injection for OA. Nanoparticles (NPs) have been shown to significantly increase medication absorption and retention in OA. Systems for delivering targeted nanomaterials have strong biocompatibility and drug loading-release capabilities.

Keywords: Nanoparticles (NPs), Osteoarthritis (OA).